Buchang Pharma subsidiary secures ibuprofen registration certificate

Shandong Buchang Pharmaceuticals Co., Ltd. announced that its wholly-owned subsidiary, Shandong Danhong Pharmaceutical Co., Ltd., has obtained a drug registration certificate from the National Medical Products Administration for Ibuprofen Sustained-Release Capsules. This approval is for a 0.3g dosage, classified as a Category 4 chemical drug for over-the-counter use, with the registration valid until Sept. 29, 2030. The drug is indicated for mild to moderate pain relief and fever.

According to data from Minai.com, annual sales of Ibuprofen Sustained-Release Capsules in urban public hospitals in China were 25,539 million yuan, 22,593 million yuan, and 20,204 million yuan for 2022, 2023, and 2024 respectively. Urban retail pharmacies reported annual sales of 111,582 million yuan, 141,079 million yuan, and 132,038 million yuan for the same period. The company invested approximately 12.06 million yuan in research and development for this project.

The company stated that this approval will optimize its product structure, maintain stable production capacity, and meet market demand, positively impacting future operations. However, pharmaceutical products are high-tech, high-risk, and high-value-added, and their production and sales can be subject to uncertainties.